A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components-Reference-Cited by-同舟云学术

A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components

Published:2016-08-02 Issue:5 Volume:15 Page:430-437
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Dong Gaohong¹,Li Di²,Ballerstedt Steffen³,Vandemeulebroecke Marc³

Affiliation:

1. iStats Inc.; Long Island City NY USA

2. Eisai Inc.; Woodcliff Lake NJ USA

3. Novartis Pharma AG; Basel Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1763/fullpdf

Reference26 articles.

1. EUnetHTA (European network for Health Technology Assessment) Endpoints used for relative effectiveness assessment of pharmaceuticals - Composite endpoints 2013 http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/ files/Composite\%20endpoints.pdf

2. Advanced multiplicity adjustment methods in clinical trials;Alosh;Statistics in Medicine,2014

3. Use of composite endpoints in clinical trials;Sankoh;Statistics in Medicine,2014

4. European Medicines Agency (EMA) Guideline on the evaluation of medicinal products for cardiovascular disease prevention 2008 http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/ 2009/09/WC500003290.pdf

5. European Medicines Agency (EMA) Points to consider on multiplicity issues in clinical trials 2002 http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2009/09/ WC500003640.pdf

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Win Statistics in Observational Cancer Research: Integrating Clinical and Quality-of-Life Outcomes;Journal of Clinical Medicine;2024-05-31

2. A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials;Nature Medicine;2024-05

3. Restricted Time Win Ratio: From Estimands to Estimation;Statistics in Biopharmaceutical Research;2024-04-26

4. Use of the Win Ratio Analysis in Critical Care Trials;American Journal of Respiratory and Critical Care Medicine;2024-04-01

5. Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial;Clinical Infectious Diseases;2024-02-02